Company Growth (employees)
Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, US
Regeneron Pharmaceuticals Office Locations
Regeneron Pharmaceuticals has offices in Tarrytown, Rensselaer, Bernards, Limerick and in 1 other location
Tarrytown, US (HQ)
777 Old Saw Mill River Rd
Dublin, IE
Harcourt Centre Harcourt St
Bernards, US
110 Allen Rd
Rensselaer, US
81 Columbia Turnpike
Regeneron Pharmaceuticals Data and Metrics
Regeneron Pharmaceuticals Financial Metrics
Regeneron Pharmaceuticals's revenue was reported to be $4.9 b in FY, 2016 which is a 18% increase from the previous period.
USD
Revenue (FY, 2016) | 4.9 b |
Revenue growth (FY, 2015 - FY, 2016), % | 18% |
Gross profit (FY, 2016) | 4.7 b |
Gross profit margin (FY, 2016), % | 96% |
Net income (FY, 2016) | 895.5 m |
EBIT (FY, 2016) | 1.3 b |
Market capitalization (26-Jun-2017) | 54.5 b |
Closing share price (26-Jun-2017) | 517.3 |
Cash (31-Dec-2016) | 535.2 m |
Regeneron Pharmaceuticals's current market capitalization is $54.5 b.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 2.1 b | 2.8 b | 4.1 b | 4.9 b |
Revenue growth, % | 34% | 46% | 18% | |
Cost of goods sold | 118 m | 129 m | 241.7 m | 194.6 m |
Gross profit | 2 b | 2.7 b | 3.9 b | 4.7 b |
Gross profit Margin, % | 94% | 95% | 94% | 96% |
Operating expense total | 1.2 b | 1.9 b | 2.6 b | 3.5 b |
EBIT | 760 m | 838.4 m | 1.3 b | 1.3 b |
EBIT margin, % | 36% | 30% | 31% | 27% |
Interest expense | 46.4 m | 37.4 m | 14.2 m | 7.2 m |
Pre tax profit | 713.4 m | 775.7 m | 1.2 b | 1.3 b |
Income tax expense | (289 m) | (427.7 m) | (589 m) | (434.3 m) |
Net Income | 424.4 m | 348.1 m | 636.1 m | 895.5 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 535.6 m | 648.7 m | 809.1 m | 535.2 m |
Inventories | 70.4 m | 128.9 m | 238.6 m | 399.4 m |
Current Assets | 1.8 b | 2.2 b | 2.9 b | 3.2 b |
PP&E | 2.1 b | |||
Total Assets | 3 b | 3.9 b | 5.6 b | 7 b |
Accounts Payable | 250.9 m | 484.2 m | 644.1 m | 879.1 m |
Current Liabilities | 298.8 m | 654.7 m | 811.2 m | 1.2 b |
Common Stock | 2 k | 2 k | 2 k | 2 k |
Additional Paid-in Capital | 2 b | 2.4 b | 3.1 b | 3 b |
Retained Earnings | (92.7 m) | 255.4 m | 852.7 m | 1.7 b |
Total Equity | 2 b | 2.5 b | 3.7 b | 4.4 b |
Financial Leverage | 1.5 x | 1.5 x | 1.5 x | 1.6 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 424.4 m | 348.1 m | 636.1 m | 895.5 m |
Depreciation and Amortization | 41.2 m | 52.7 m | 74.9 m | 104.7 m |
Inventories | (48 m) | (61 m) | (110 m) | (150 m) |
Cash From Operating Activities | 583.6 m | 743.2 m | 1.3 b | 1.5 b |
Capital Expenditures | (156.3 m) | (333 m) | (677.9 m) | (511.9 m) |
Cash From Investing Activities | (355.5 m) | |||
Cash From Financing Activities | (209.3 m) | (262.8 m) | (700.4 m) | |
Interest Paid | 23.8 m | 20.6 m | 10.6 m | 5.5 m |
Income Taxes Paid | 59.8 m | 276.1 m | 481.4 m | |
Free Cash Flow | 740 m | 1.1 b | 2 b | 2 b |
| USD | Y, 2016 |
|---|---|
Revenue/Employee | 1 m |
Financial Leverage | 1.6 x |
Regeneron Pharmaceuticals Market Value History
Regeneron Pharmaceuticals Median Salaries
Source: 186 public H-1B filings from Regeneron Pharmaceuticals
